RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges

Comments
Loading...
Zinger Key Points

RxSight, Inc. RXST shares are trading lower premarket on Thursday.

On Wednesday, the company disclosed first-quarter preliminary results and revised its FY25 outlook.

The company sees first-quarter revenue of around $37.9 million, up 28% year over year and down 6% quarter over quarter, and below the consensus of $40.14 million.

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume.

Also, the company anticipates the sale of 73 Light Delivery Devices (LDDs), increasing the installed base to 1,044 LDDs by March 31, 2025, marking a 43% Y/Y growth.

Revised FY25 Outlook: The company lowered the revenue outlook to $160.0 million – $175.0 million (vs. consensus of $188.9 million) from $185.0 million – $197.0 million earlier.

Also, RxSight curtailed the operating expenses outlook to $150 million – $160 million from $165 million – $170 million prior.

Ron Kurtz, Chief Executive Officer and President of RxSight, said, “Given RxSight’s more significant installed base of surgeons and practices, we now must navigate headwinds affecting the overall premium IOL market and broader economy that were less impactful when our commercial footprint was much smaller.”

“To address current market conditions, as well as our long-term opportunity to transform the practice of premium cataract surgery, we will continue to refine our clinical education and practice adoption programs, support new customer business models, drive innovative product enhancements and advance international expansion.”

The company expects to announce the first quarter of 2025 results on Wednesday, May 7, 2025.

In February, RxSight reported fourth quarter adjusted EPS of $0.03, a notable improvement from $(0.13) year-over-year. Sales totaled $40.214 million, slightly missing the $40.318 million estimate.

Price Action: RXST shares are down 23.9% at $19.90 premarket at the last check Thursday.

Read Next:

Photo via Shutterstock.

RXST Logo
RXSTRxSight Inc
$14.43-0.65%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
3.93
Growth
87.19
Quality
-
Value
61.00
Price Trend
Short
Medium
Long
Got Questions? Ask
Which premium cataract surgery companies might gain from RxSight's challenges?
How could RxSight's revised FY25 outlook impact investor sentiment?
Which medical device stocks are undervalued amid RxSight's decline?
How will RxSight's operating expense cuts affect its profitability?
Could RxSight's international expansion create new market opportunities?
What other companies in the IOL market could be affected by RxSight's performance?
How does RxSight's surgeon base expansion influence competitor strategies?
What potential partnerships could emerge from RxSight's market navigation efforts?
How might investor confidence be swayed by RxSight's current stock plunge?
Which healthcare ETFs could be impacted by shifts in the premium IOL market?
Market News and Data brought to you by Benzinga APIs

Posted In: